Menu
Search
|

Menu

Close
X

Theravance Biopharma Inc TBPH.OQ (NASDAQ Stock Exchange Global Market)

18.16 USD
+0.06 (+0.33%)
As of Jul 23
Previous Close 18.10
Open 18.19
Volume 101,538
3m Avg Volume 91,988
Today’s High 18.41
Today’s Low 18.00
52 Week High 35.48
52 Week Low 15.18
Shares Outstanding (mil) 53.83
Market Capitalization (mil) 1,919.56
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.75 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY19
5
FY18
60
FY17
15
FY16
49
EPS (USD)
FY19
-1.321
FY18
-3.996
FY17
-5.448
FY16
-4.251
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
61.20
7.92
Price to Book (MRQ)
vs sector
7.96
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
92.57
14.56
LT Debt to Equity (MRQ)
vs sector
92.57
10.21
Return on Investment (TTM)
vs sector
-57.04
14.49
Return on Equity (TTM)
vs sector
-82.78
15.79

EXECUTIVE LEADERSHIP

Rick Winningham
Chairman of the Board, Chief Executive Officer, Since
Salary: $956,600.00
Bonus: $74,767.00
Andrew Hindman
Chief Financial Officer, Senior Vice President, Since 2019
Salary: --
Bonus: --
Ann Brady
President - Theravance Biopharma Ireland Limited, Since 2016
Salary: --
Bonus: --
Bradford Shafer
Executive Vice President, General Counsel, Secretary, Since 2016
Salary: $518,080.00
Bonus: $33,770.00
.. ..
Senior Vice President - Technical Operations, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

UGLAND HOUSE, SOUTH CHURCH STREE
GEORGE TOWN     KY1-1104

Phone: +1345.6508086000

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

SPONSORED STORIES